The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
Positron Emission Tomography Imaging of Participants with Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded review, Dose Ranging Phase I study.
To be considered for the study you must meet the following criteria:
- Signed, informed consent
- >18 years of age
- Diagnosis of prostate cancer\Prostate Specific Antigen level >10ng/ml, and/or Gleason Score of 7 (4+3) or above, and/or clinical stage greater than or equal to T2b
This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer. The new compound is called 64Cu-SAR-bisPSMA.
64Cu-SAR-bisPSMA given as an injection in the vein in preparation for an imaging test that may help detect cancer (called positron emission tomography/computed tomography or PET/CT scan imaging). 64Cu-SAR-bisPSMA is designed to be attracted to prostate tumour cells and has a small dose of radiation added to it, which may help doctors see the cancer cells better during imaging scans.
The main purpose of this study is to see how well 64Cu-SAR-bisPSMA is tolerated at different doses, and how well the 64Cu-SAR-bisPSMA PET/CT scan detects tumours compared to a similar imaging test called 68Ga-PSMA-11 PET/CT.